Compare ELS & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELS | TECH |
|---|---|---|
| Founded | 1992 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 11.4B |
| IPO Year | 1994 | 1995 |
| Metric | ELS | TECH |
|---|---|---|
| Price | $61.29 | $72.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $70.25 | ★ $71.82 |
| AVG Volume (30 Days) | 1.2M | ★ 2.3M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.49% | 0.62% |
| EPS Growth | 2.55 | ★ 152.17 |
| EPS | 0.56 | ★ 1.16 |
| Revenue | ★ $1,531,382,000.00 | $1,215,039,000.00 |
| Revenue This Year | $3.97 | $2.49 |
| Revenue Next Year | $4.69 | $6.40 |
| P/E Ratio | $107.29 | ★ $62.19 |
| Revenue Growth | ★ 0.34 | N/A |
| 52 Week Low | $58.72 | $43.20 |
| 52 Week High | $69.00 | $72.62 |
| Indicator | ELS | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 38.85 | 59.26 |
| Support Level | $61.22 | $72.14 |
| Resistance Level | $63.83 | $72.37 |
| Average True Range (ATR) | 0.93 | 0.16 |
| MACD | -0.33 | -0.15 |
| Stochastic Oscillator | 30.82 | 45.24 |
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company has a portfolio of 453 properties across the US with a higher concentration in the Sun Belt; 38% of its properties are in Florida, 11% in Arizona, and 10% in California. Equity Lifestyle targets owning properties in attractive retirement destinations. More than 70% of the company's properties are either age-restricted or have an average resident age over 55.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.